Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / articles / MESO - Analyst Bullish On Cell Therapy Player Mesoblast But Cuts Price Target | Benzinga

MESO - Analyst Bullish On Cell Therapy Player Mesoblast But Cuts Price Target | Benzinga

Mesoblast Limited

Wednesday, Mesoblast Ltd (NASDAQ: MESO) FY23 results, with revenues of $7.5 million for FY2023, compared to $10.2 million in FY2022, missing the consensus of $7.97 million.

The company reported narrower EPS loss of $(0.11), beating the consensus of $(0.57).

Citing solid Q4 earnings, Cantor Fitzgerald reiterates the Overweight rating but lowered the price target from $23 to $17

Earlier this month, the FDA issued a complete response letter to Mesoblast's resubmission for remestemcel-L for pediatric steroid-refractory acute graft versus host disease (SR-aGVHD), Full story available on Benzinga.com
Stock Information
Company Name: Mesoblast Limited
Stock Symbol: MESO
Market: NASDAQ
Website: mesoblast.com
Menu
MESO MESO Quote MESO Short MESO News MESO Articles MESO Message Board
Get MESO Alerts

News, Short Squeeze, Breakout and More Instantly...